MIRA Pharmaceuticals Shares Are Trading Higher After the Company Announced a Recent Pre-clinical Study in Rats Demonstrated That Ketamir-2 Produced a Significant Reversal of Neuropathic Pain, Induced by Nerve Ligation, Culminating in a 100%...

Benzinga · Aug 26 20:43

MIRA Pharmaceuticals Shares Are Trading Higher After the Company Announced a Recent Pre-clinical Study in Rats Demonstrated That Ketamir-2 Produced a Significant Reversal of Neuropathic Pain, Induced by Nerve Ligation, Culminating in a 100% Normalization of Pain Thresholds at the Highest Dose.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

MIRA Pharmaceuticals Shares Are Trading Higher After the Company Announced a Recent Pre-clinical Study in Rats Demonstrated That Ketamir-2 Produced a Significant Reversal of Neuropathic Pain, Induced by Nerve Ligation, Culminating in a 100%...

MIRA Pharmaceuticals Shares Are Trading Higher After the Company Announced a Recent Pre-clinical Study in Rats Demonstrated That Ketamir-2 Produced a Significant Reversal of Neuropathic Pain, Induced by Nerve Ligation, Culminating in a 100% Normalization of Pain Thresholds at the Highest Dose.

Risk Disclaimer